10-Q: Xtant Medical Holdings Q1 2026 Results Show Revenue Decline

Xtant Medical Holdings reported a 37% decrease in total revenue for the first quarter of 2026 compared to the prior year, primarily due to asset divestitures and a reduction in license revenue.

Summary

• Total revenue for the first quarter ended March 31, 2026, decreased by 37% to $20.9 million, down from $32.9 million in the same period of 2025.
• This decline was primarily driven by the divestiture of Coflex/CoFix assets and the international hardware business, contributing a $5.4 million reduction, and a $3.6 million decrease in license revenue.
• Product revenue also saw a decrease, mainly from skin substitute products, impacted by changes in the reimbursement environment effective January 1, 2026.
• Cost of sales decreased by 30% to $8.9 million, largely in line with the reduction in revenue.
• Gross profit margin decreased to 57.3% from 61.5% in the prior year, attributed to reduced scale and a change in sales mix, particularly the impact of lower license revenue.
• Operating expenses also decreased, with General and Administrative expenses down 17% to $6.3 million and Sales and Marketing expenses down 27% to $8.2 million, both benefiting from the asset divestitures.
• The company reported a net loss of $3.1 million for the quarter, compared to a net income of $0.1 million in the prior year.
• Net cash used in operating activities was $2.1 million, a shift from net cash provided by operating activities of $1.3 million in the prior year.
• The company entered into a new Distribution Agreement with Dilon Technologies, Inc. on April 13, 2026, for the exclusive rights to distribute the HEMOBLAST Bellows product in the United States, involving a $5.0 million exclusivity fee.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant revenue decline, the shift to a net loss, and the ongoing challenges with internal controls, despite strategic initiatives like the new distribution agreement.

Positives

• The company successfully completed the sale of certain non-core assets related to Coflex and CoFix products and its international hardware business, generating proceeds that were used to repay debt.
• A new exclusive distribution agreement for the HEMOBLAST Bellows product was secured with Dilon Technologies, Inc., expanding the product portfolio and sales capabilities.
• The company has $12.2 million in cash and cash equivalents as of March 31, 2026, and anticipates sufficient liquidity through at least May 2027.
• Amendments to credit agreements were made to adjust covenants, including eliminating the minimum net revenue covenant for Q4 2025 and revising it to focus on orthobiologics revenue.

Negatives

• Total revenue decreased by 37% to $20.9 million in Q1 2026 compared to $32.9 million in Q1 2025.
• Net loss for the quarter was $3.1 million, a significant shift from a net income of $0.1 million in the prior year.
• Gross profit margin declined to 57.3% from 61.5% due to reduced scale and a change in sales mix, particularly the loss of higher-margin license revenue.
• The company experienced a net cash outflow from operating activities of $2.1 million in Q1 2026, compared to a net cash inflow of $1.3 million in Q1 2025.
• The company paid a $5.0 million exclusivity fee for the HEMOBLAST Bellows distribution agreement, which is subject to repayment under certain termination conditions.
• A material weakness in internal control over financial reporting related to the evaluation of inventory net realizable value was previously identified and is still being remediated.

Risks

• The company faces risks associated with the new exclusive distribution agreement with Dilon Technologies, Inc., including the success of selling the HEMOBLAST Bellows product, integration with the existing portfolio, and potential termination of the agreement.
• Increased sales and marketing expenses are expected due to the Dilon agreement and the hiring of new sales personnel, with no assurance that the additional revenue will offset these costs.
• Reliance on Dilon as the sole manufacturer of the HEMOBLAST Bellows product, with no control over the manufacturing process or potential risks associated with international operations in France.
• The potential for future dilution to existing stockholders if additional capital is raised through equity or convertible debt financings.
• The company's significant indebtedness and the covenants in its credit agreements could restrict its ability to take certain actions.
• The material weakness in internal control over financial reporting related to inventory valuation could lead to future material misstatements if not effectively remediated.
• The loss of revenue from the divested Coflex/CoFix products and international hardware business will adversely affect 2026 revenue.
• Changes in reimbursement environments, such as those affecting the SimpliMax product, can negatively impact revenue and gross margins.

Future Outlook

The company anticipates that its current cash and cash equivalents, along with anticipated operating cash flows and amounts available under its credit facilities, will be sufficient to meet its cash requirements through at least May 2027. However, it may require or seek additional capital before then, potentially through equity or debt financings, debt restructurings, or strategic transactions. The company expects sales and marketing expenses to increase in future periods due to the new distribution agreement with Dilon.

Management Comments

• The loss of revenue from the divested Coflex/CoFix products and international hardware business will adversely affect our 2026 revenue.
• The reduction in license revenue, primarily related to changes in the reimbursement environment for our SimpliMax product, will adversely affect a portion of our product revenue in 2026.
• We expect our sales and marketing expenses to increase in future periods due to our exclusive distribution agreement with Dilon and our recent hiring of approximately 20 sales personnel in connection therewith to assist in the sale of the HEMOBLAST Bellows product in the United States.
• While our working capital decreased by $4.9 million as of March 31, 2026 as compared to December 31, 2025, we used cash received from the Companion Spine transaction to repay some of our long-term debt.

Industry Context

StockSavvy.ai notes that Xtant Medical Holdings' Q1 2026 results reflect significant strategic shifts, including asset divestitures and new distribution agreements, which are common in the competitive medical technology sector. The decline in revenue is partly attributed to changes in reimbursement policies, a persistent challenge for companies in the healthcare industry.

Comparison to Industry Standards

• The reported gross margin of 57.3% is within the typical range for medical device companies, though the decline from 61.5% warrants attention.
• The net loss of $3.1 million for the quarter, while concerning, is not uncommon for companies undergoing significant restructuring or investing in new product lines, especially in the specialized orthobiologics and spinal implant market.
• The company's focus on orthobiologics and spinal implants aligns with a growing segment of the healthcare market driven by an aging population and advancements in surgical techniques. Competitors in this space include companies like NuVasive, Globus Medical, and Stryker, which also focus on spinal and orthopedic solutions.

Corporate Governance

Legal Proceedings

• The company may be subject to potential liabilities under government regulations and various claims and legal actions, including commercial, product liability, intellectual property, and employment matters. While currently believed to be immaterial, unfavorable resolutions could materially affect cash flows or results of operations.

Stakeholder Impact

• Shareholders: Potential dilution from future capital raises, impact of net loss on stock value, and ongoing efforts to remediate internal control weaknesses.
• Employees: Hiring of approximately 20 sales personnel in connection with the Dilon agreement, but potential reassignment or termination if the agreement terminates.
• Creditors: The company is in compliance with its credit agreement covenants as of March 31, 2026, but significant indebtedness and covenants could impact future flexibility.
• Suppliers: Reliance on Dilon as the sole manufacturer for HEMOBLAST Bellows, with potential risks related to supply and pricing.

Next Steps

• Continue to implement measures to remediate the material weakness in internal control over financial reporting.
• Integrate the HEMOBLAST Bellows product and the new sales team into the company's operations.
• Monitor and manage sales and marketing expenses related to the new distribution agreement.
• Continue to assess the need for and explore potential sources of additional capital.

Key Dates

Recommendation

The company is undergoing significant strategic changes, including asset divestitures and a new distribution agreement, which introduce both opportunities and risks. The revenue decline and net loss are concerning, as is the ongoing material weakness in internal controls. However, the company has secured new product distribution and appears to have sufficient liquidity in the near term. A 'hold' recommendation reflects the uncertainty and the need to observe the execution of the new strategy and the remediation of control issues before considering a more definitive stance.

Keywords

Xtant Medical Holdings, Form 10-Q, Quarterly Report, Orthobiologics, Spinal Implants, Revenue Decline, Asset Sale, Distribution Agreement, HEMOBLAST Bellows, Financial Results, Net Loss, Inventory Valuation